# LUX-Lung 2 (NCT00525148)

> LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations

No report yet. It can be ordered.

- Drugs tested: afatinib
- Indication: EGFR-mutated advanced non-small-cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT00525148
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Boehringer Ingelheim
- Conditions: Carcinoma, Non-Small-Cell Lung
- Interventions: BIBW 2992
- Enrollment: 129
- Primary outcome: Objective Response (OR) as Determined by RECIST 1.0

## Indexed commentary on LUX-Lung 2 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=lux-lung-2-nct00525148
